1. Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMA
- Author
-
Fabio Efficace, Wael Al Essa, Uwe Platzbecker, Pasquale Niscola, Giuseppe A. Palumbo, Giovanni Caocci, Francesco Cottone, Massimo Breccia, Mario Luppi, Reinhard Stauder, Alessandra Ricco, Duska Petranovic, Frederic Baron, Maria Teresa Voso, Luana Fianchi, Chiara Frairia, Isabella Capodanno, Chiara Sarlo, Marilena Fedele, Roberto Massimo Lemoli, Rosangela Invernizzi, Daniele Vallisa, Nicola Di Renzo, Claudio Fozza, Maribel Doro, Johannes M. Giesinger, and Marco Vignetti
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Health-related quality of life (HRQoL) is an important goal of therapy for patients with myelodysplastic syndromes (MDS); however, little is known about HRQoL of these patients at clinical presentation. We report HRQoL profile of newly diagnosed patients with MDS across both the the International Prognostic Scoring System (IPSS) and IPSS-Revised (IPSS-R) classifications, stratified by sex and age group categories, aiming to also establish European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core30 (EORTC QLQ-C30) reference values for these patients. Analysis was based on 927 patients with a median age of 73.3 years (interquartile range, 66.0–79.2), of whom 506 and 421 with lower- and higher-risk disease respectively, according to the IPSS classification. HRQoL was assessed with the EORTC QLQ-C30 and substantial differences by age groups and sex, between and within lower- and higher-risk disease categories were observed. For example, within higher-risk disease patients, the youngest group (ie, 30–59 years) tended to report clinically meaningful worse outcomes across various functional and symptom domains compared with older age groups. We also developed 2 regression models allowing for the prediction of EORTC QLQ-C30 reference scores for patients classified according to either the IPSS or the IPSS-R. Investigation of prevalence rates for clinically important problems and symptoms at diagnosis revealed a substantial burden of the disease with >50% of patients reporting clinically important problems with physical functioning and dyspnea in both lower- and higher-risk disease. Our findings may help to enhance the interpretation of HRQoL outcomes in future MDS studies and to better contextualize HRQoL data from routine practice settings.
- Published
- 2023
- Full Text
- View/download PDF